Agent for treatment of schizophrenia

  • US 9,815,827 B2
  • Filed: 08/28/2014
  • Issued: 11/14/2017
  • Est. Priority Date: 08/22/2002
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating schizophrenia in a patient without a clinically significant weight gain, comprising:

  • administering orally to the patient (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof at a dose of from 20 to 120 mg/day such that the patient does not experience a clinically significant weight gain.

View all claims

    Thank you for your feedback